Manage LDL Cholesterol Level with Evolocumab to Prevent Severe Cardiovascular Outcome
|
Reviewed & Translated by Dat Tien Nguyen, B.A, ScM.
|
Posted on February 6th, 2026
|
Elevated levels of low-density lipoprotein (LDL) cholesterol promote plaque formation along the vascular endothelium, leading to luminal narrowing and impaired blood flow. This process substantially increases the risk of atherosclerotic cardiovascular events, including myocardial infarction and ischemic stroke. With funding from Amgen, a large clinical study was conducted to evaluate the effectiveness of evolocumab in preventing major cardiovascular outcomes.
The trial enrolled 12,257 participants with a median age of 66 years. At baseline, the cohort had mean LDL cholesterol and triglyceride levels of 122 mg/dL and 153 mg/dL, respectively. Most participants (92%) were receiving background lipid-lowering therapy, including statins in 68% of patients and ezetimibe in 19%.
Participants were randomly assigned to receive subcutaneous injections of either placebo or evolocumab at a dose of 140 mg every two weeks. Evolocumab is a monoclonal antibody that inhibits proprotein convertase subtilisin/kexin type 9 (PCSK9), a protein synthesized by hepatocytes and released into the circulation. PCSK9 binds to LDL receptors and promotes their degradation, thereby reducing LDL clearance. By blocking PCSK9 activity, evolocumab increases the availability of LDL receptors on hepatocytes and enhances removal of LDL cholesterol from the bloodstream.
After a follow-up period of five years, patients treated with evolocumab experienced a 25% reduction in the risk of myocardial infarction, ischemic stroke, or coronary heart disease compared with placebo. Treatment with evolocumab was also associated with a reduction in cardiovascular mortality. Subgroup analyses indicated greater benefit among patients receiving high-intensity statin therapy who had baseline LDL cholesterol levels between 122 and 149 mg/dL. The extended duration of follow-up in this trial reinforces prior evidence supporting PCSK9 inhibition as an effective strategy for reducing cardiovascular risk.
The trial enrolled 12,257 participants with a median age of 66 years. At baseline, the cohort had mean LDL cholesterol and triglyceride levels of 122 mg/dL and 153 mg/dL, respectively. Most participants (92%) were receiving background lipid-lowering therapy, including statins in 68% of patients and ezetimibe in 19%.
Participants were randomly assigned to receive subcutaneous injections of either placebo or evolocumab at a dose of 140 mg every two weeks. Evolocumab is a monoclonal antibody that inhibits proprotein convertase subtilisin/kexin type 9 (PCSK9), a protein synthesized by hepatocytes and released into the circulation. PCSK9 binds to LDL receptors and promotes their degradation, thereby reducing LDL clearance. By blocking PCSK9 activity, evolocumab increases the availability of LDL receptors on hepatocytes and enhances removal of LDL cholesterol from the bloodstream.
After a follow-up period of five years, patients treated with evolocumab experienced a 25% reduction in the risk of myocardial infarction, ischemic stroke, or coronary heart disease compared with placebo. Treatment with evolocumab was also associated with a reduction in cardiovascular mortality. Subgroup analyses indicated greater benefit among patients receiving high-intensity statin therapy who had baseline LDL cholesterol levels between 122 and 149 mg/dL. The extended duration of follow-up in this trial reinforces prior evidence supporting PCSK9 inhibition as an effective strategy for reducing cardiovascular risk.